Incyte Corp

3.07.2026 г., 00:01 ч. UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market conditions may be influencing investor sentiment.

2.07.2026 г., 23:01 ч. UTC

Incyte Corp shares declined in after-market hours amid notable volatility, contrasting with three consecutive sessions of gains. No specific news was identified for the move.

1.07.2026 г., 21:01 ч. UTC

Incyte Corp shares are higher in after-market trading, reflecting a notable increase as they approach the upper end of their one-month range.

30.06.2026 г., 23:01 ч. UTC

Incyte Corp shares are higher in after-market trading, maintaining an upward trend despite broader market declines, particularly in the tech sector.

29.06.2026 г., 23:16 ч. UTC

Incyte Corp shares are higher in after-market trading following positive results from the Phase 2b trial of EVO756 for chronic spontaneous urticaria.

26.06.2026 г., 23:51 ч. UTC

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

25.06.2026 г., 23:51 ч. UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

24.06.2026 г., 20:02 ч. UTC

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to the stock's advance amid positive social media sentiment.

23.06.2026 г., 19:46 ч. UTC

Incyte Corp shares are higher today, reflecting a cumulative gain since Monday. The stock has rebounded from an earlier session pullback amid broader market pressures.

22.06.2026 г., 20:02 ч. UTC

Incyte Corp's stock is higher after Japan approved Minjuvi for lymphoma treatment. BMO upgraded the company to Market Perform and raised its price target to $94.

18.06.2026 г., 22:16 ч. UTC

Incyte Corp shares are trading higher in after-market hours. No specific news was identified to explain this movement amid a broader market uptrend.

17.06.2026 г., 23:46 ч. UTC

Incyte Corp shares are lower in after-market trading following significant volatility. Broader market trends may be affecting investor sentiment amid stronger U.S. retail sales.

16.06.2026 г., 19:22 ч. UTC

Incyte shares are lower despite positive phase II study results for zilurgisertib. The FDA has begun Priority Review of the New Drug Application.

15.06.2026 г., 14:23 ч. UTC

Incyte Corp's stock is lower as analysts raise concerns over clinical data despite promising Phase 3 trial results for tafasitamab.

12.06.2026 г., 22:02 ч. UTC

Incyte Corp shares are lower in after-market hours, continuing a trend of unusual weakness since Friday's close, with no specific news identified.

11.06.2026 г., 22:02 ч. UTC

Incyte Corp shares are lower in after-market hours, despite being above their 20-day moving average and three consecutive sessions of higher closes.

10.06.2026 г., 21:02 ч. UTC

Incyte shares rise in after-market trading on Guggenheim target increase.

9.06.2026 г., 20:02 ч. UTC

Incyte Corp gains as HC Wainwright raises price target to $140 and the company announces a $1.25 billion acquisition of Vega Therapeutics.

8.06.2026 г., 19:42 ч. UTC

Incyte Corp shares are lower after announcing a $1.25 billion acquisition of Vega Therapeutics, which will impact upcoming financial results significantly.

5.06.2026 г., 22:51 ч. UTC

Incyte Corp shares are higher in after-market trading, reflecting positive market sentiment following stronger-than-expected U.S. job growth data.

4.06.2026 г., 20:01 ч. UTC

Incyte shares rise as results from the Phase 2 PROGRESS study will be presented at ENDO 2026, supporting the FDA's Priority Review of its application.

3.06.2026 г., 20:02 ч. UTC

Incyte Corp shares are higher today, breaking a recent trend. The ADP Employment Report showed stronger-than-expected job growth, influencing broader market sentiment.

2.06.2026 г., 23:06 ч. UTC

Incyte Corp. shares are trading roughly flat in after-market hours, following a session that saw a peak gain earlier.

1.06.2026 г., 19:36 ч. UTC

Incyte Corp's stock is lower after the Phase 3 frontMIND trial results raised safety concerns despite showing efficacy in treating high-risk lymphoma patients.

29.05.2026 г., 23:46 ч. UTC

Incyte Corp shares are lower in after-market hours, reflecting a slight decline since Friday's close without any specific news to explain the movement.

28.05.2026 г., 20:06 ч. UTC

Incyte Corp shares are higher today, recovering from earlier losses amid modest overall market performance. No specific company news was identified to explain the movement.

27.05.2026 г., 23:06 ч. UTC

Incyte Corp. shares remain roughly flat in after-market trading, with no specific news identified and movement within a narrow range since Wednesday's close.

26.05.2026 г., 20:06 ч. UTC

Incyte Corp. shares are lower today, reflecting a decline since Friday's close amid broader market focus on upcoming economic data releases.

21.05.2026 г., 19:26 ч. UTC

HC Wainwright & Co. reiterated a Buy rating on Incyte Corp with a $135 price target, contributing to the stock's upward movement since Wednesday.